 |

The use of a newly licensed HPV vaccine,
appropriate patient population, the effect and
outcomes of the HPV-6, 11, 16, 18 vaccine on
immunogenicity against the HPV virus in women,
and safety and efficacy results from large clinical
trials with HPV vaccines. |
 |

Use for newly licensed vaccines will be reviewed to include the new meningococcal conjugate vaccines and the new tetinus-diphtheria-acellular pertussis vaccine for adolescents. Also, vaccines will be discussed with anticipated approval. |
 |